Yeah, it could- a little bit. However, unlike Neurontin, Lyrica has benefitted from fairly long term direct-to-consumer marketing. As I write this I'm watching a Lyrica commercial on television, actually. Weird, two in a row- Lyrica followed by Humira.
The biggest factor has to be scheduling. Off-label scheduling was so incredibly common with Neurontin was common for a number of reasons, I doubt that in-office conversations sales people had with doctors contributed even 10%, though.
Lyrica isn't being prescribed off-label because it's scheduled. For one, doc's don't like to prescribe anything that's scheduled. Some less so than others (to be a little pedantic, some probably do like to, but that's a real minority), but none want to risk accusations of malpractice. At least as sizable a reason is the insurance companies. They hate paying for off-label use of prescription drugs, and really really hate paying for off-label use of controlled drugs. My insurance would gladly pay for gabapentin to treat anxiety, but would never consider Lyrica for the same purpose.
Anyway, the point is moot. Ultimately the DEA denied my request for a hearing because I failed to meet the definition of an "interested person."
Trying again with the JWH ban.